PFE
Pfizer Inc.
Price Chart
Latest Quote
$26.04
+0.35 (+1.36%)
Current Price
| Previous Close | $25.69 |
| Open | $25.85 |
| Day High | $26.21 |
| Day Low | $25.79 |
| Volume | 31,753,014 |
Stock Information
| Quarterly Dividend / Yield | $1.72 / 6.70% |
| Shares Outstanding | 5.70B |
| Quarterly Dividend Yield | 6.70% |
| Quarterly Dividend | $1.72 |
| Total Debt | $64.73B |
| Cash Equivalents | $13.08B |
| Revenue | $63.32B |
| Net Income | $7.48B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $148.41B |
| P/E Ratio | 19.88 |
| EPS (TTM) | $1.31 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $198.37B |
| Sales | $63.32B |
| Income | $7.48B |
| Book/sh | $15.81 |
| Cash/sh | $2.30 |
| Employees | 75K |
Financial Ratios
| Quick Ratio | 0.85 |
| Current Ratio | 1.25 |
| Debt/Eq | 71.60 |
| EPS Growth TTM | -9.40% |
Returns & Margins
| ROA | 5.69% |
| ROE | 8.31% |
| Gross Margin | 74.80% |
| Operating Margin | 31.62% |
| Profit Margin | 11.83% |
Ownership
| Insider Ownership | 0.10% |
| Institutional Ownership | 69.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 9.18 |
| PEG | 13.77 |
| P/S | 2.34 |
| P/B | 1.65 |
Analyst Data
| Recommendation | buy |
| Target Price | $29.19 |
Technical Indicators
| SMA20 | $25.78 |
| SMA50 | $26.33 |
| SMA200 | $25.14 |
| RSI | 63.00 |
| ATR | 0.4450 |
| Shares Float | 5.69B |
| Short Float | 2.76% |
| Short Ratio | 4.34 |
| Volatility | 0.29 |
| Rel Volume | 0.95 |
Performance History
| Week | -0.53% |
| Month | -0.23% |
| Quarter | -2.14% |
| 6 Months | +5.25% |
| YTD | +6.88% |
| Year | +19.11% |
| 3 Years | -17.46% |
| 5 Years | -13.13% |
| 10 Years | +22.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $26.04 | 31,753,014 |
| 2026-06-04 | $25.69 | 31,272,000 |
| 2026-06-03 | $25.34 | 30,957,100 |
| 2026-06-02 | $25.55 | 31,295,700 |
| 2026-06-01 | $25.63 | 35,553,600 |
| 2026-05-29 | $26.18 | 48,284,200 |
| 2026-05-28 | $26.14 | 25,651,800 |
| 2026-05-27 | $26.21 | 39,024,700 |
| 2026-05-26 | $25.85 | 29,084,700 |
| 2026-05-22 | $25.90 | 22,320,000 |
| 2026-05-21 | $25.95 | 20,181,500 |
| 2026-05-20 | $25.79 | 35,574,200 |
| 2026-05-19 | $25.66 | 41,036,700 |
| 2026-05-18 | $25.33 | 34,111,300 |
| 2026-05-15 | $25.33 | 37,110,100 |
| 2026-05-14 | $25.75 | 24,102,700 |
| 2026-05-13 | $25.96 | 39,420,000 |
| 2026-05-12 | $25.87 | 26,819,500 |
| 2026-05-11 | $25.81 | 43,558,000 |
| 2026-05-08 | $25.68 | 38,903,400 |
| 2026-05-07 | $26.05 | 48,346,000 |
| 2026-05-06 | $26.10 | 40,357,100 |
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
đ° Latest News
Pfizer licenses Chai Discovery AI platform for drug discovery
Quartz âĸ 2026-06-05T13:41:54Z
Pfizer signs licence agreement with Chai for AI drug discovery
Pharmaceutical Technology âĸ 2026-06-05T10:17:54Z
75% Upside For LLY Stock?
Trefis âĸ 2026-06-04T20:23:28Z
Pfizer Taps Chai Discovery AI To Expand Biologics Pipeline Potential
Simply Wall St. âĸ 2026-06-04T19:12:07Z
Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:24Z
Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?
Zacks âĸ 2026-06-04T14:01:00Z
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
BioPharma Dive âĸ 2026-06-04T09:22:00Z
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
Motley Fool âĸ 2026-06-04T06:50:00Z
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
MarketBeat âĸ 2026-06-03T22:04:39Z
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
Motley Fool âĸ 2026-06-03T19:20:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $14,349,000,000 | $16,124,000,000 | $23,397,000,000 | $32,889,000,000 |
| Cost Of Revenue | $16,067,000,000 | $17,851,000,000 | $24,954,000,000 | $34,344,000,000 |
| Total Revenue | $62,579,000,000 | $63,627,000,000 | $59,554,000,000 | $101,175,000,000 |
| Operating Revenue | $62,579,000,000 | $63,627,000,000 | $59,554,000,000 | $101,175,000,000 |
| Expenses | ||||
| Interest Expense | $2,671,000,000 | $3,091,000,000 | $2,209,000,000 | $1,238,000,000 |
| Total Expenses | $46,785,000,000 | $48,797,000,000 | $55,331,000,000 | $64,011,000,000 |
| Other Income Expense | $-6,206,000,000 | $-4,261,000,000 | $-2,580,000,000 | $-1,447,000,000 |
| Other Non Operating Income Expenses | $1,143,000,000 | $113,000,000 | $1,068,000,000 | $1,178,000,000 |
| Net Non Operating Interest Income Expense | $-2,068,000,000 | $-2,546,000,000 | $-585,000,000 | $-987,000,000 |
| Interest Expense Non Operating | $2,671,000,000 | $3,091,000,000 | $2,209,000,000 | $1,238,000,000 |
| Operating Expense | $30,718,000,000 | $30,946,000,000 | $30,377,000,000 | $29,667,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $7,746,000,000 | $8,020,000,000 | $2,134,000,000 | $31,366,000,000 |
| Net Interest Income | $-2,068,000,000 | $-2,546,000,000 | $-585,000,000 | $-987,000,000 |
| Interest Income | $603,000,000 | $545,000,000 | $1,624,000,000 | $251,000,000 |
| Normalized Income | $13,551,710,000 | $11,556,040,000 | $5,414,870,000 | $34,133,144,000 |
| Net Income From Continuing And Discontinued Operation | $7,771,000,000 | $8,031,000,000 | $2,119,000,000 | $31,372,000,000 |
| Net Income Common Stockholders | $7,771,000,000 | $8,031,000,000 | $2,119,000,000 | $31,372,000,000 |
| Net Income | $7,771,000,000 | $8,031,000,000 | $2,119,000,000 | $31,372,000,000 |
| Net Income Including Noncontrolling Interests | $7,812,000,000 | $8,062,000,000 | $2,158,000,000 | $31,407,000,000 |
| Net Income Discontinuous Operations | $25,000,000 | $11,000,000 | $-15,000,000 | $6,000,000 |
| Net Income Continuous Operations | $7,787,000,000 | $8,051,000,000 | $2,172,000,000 | $31,401,000,000 |
| Pretax Income | $7,520,000,000 | $8,023,000,000 | $1,058,000,000 | $34,729,000,000 |
| Special Income Charges | $-7,547,000,000 | $-5,756,000,000 | $-6,219,000,000 | $-2,102,000,000 |
| Earnings From Equity Interest | $0 | $102,000,000 | $505,000,000 | $436,000,000 |
| Interest Income Non Operating | $603,000,000 | $545,000,000 | $1,624,000,000 | $251,000,000 |
| Operating Income | $15,794,000,000 | $14,830,000,000 | $4,223,000,000 | $37,164,000,000 |
| Depreciation Amortization Depletion Income Statement | $4,874,000,000 | $5,286,000,000 | $4,733,000,000 | $3,609,000,000 |
| Depreciation And Amortization In Income Statement | $4,874,000,000 | $5,286,000,000 | $4,733,000,000 | $3,609,000,000 |
| Amortization Of Intangibles Income Statement | $4,874,000,000 | $5,286,000,000 | $4,733,000,000 | $3,609,000,000 |
| Gross Profit | $46,512,000,000 | $45,776,000,000 | $34,600,000,000 | $66,831,000,000 |
| Per Share | ||||
| Diluted EPS | $1.36 | $1.41 | $0.37 | $5.47 |
| Basic EPS | $1.37 | $1.42 | $0.38 | $5.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,543,290,000 | $-939,960,000 | $-872,130,000 | $-293,856,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $24,132,000,000 | $22,603,000,000 | $13,710,000,000 | $44,092,000,000 |
| Total Unusual Items | $-7,349,000,000 | $-4,476,000,000 | $-4,153,000,000 | $-3,061,000,000 |
| Total Unusual Items Excluding Goodwill | $-7,349,000,000 | $-4,476,000,000 | $-4,153,000,000 | $-3,061,000,000 |
| Reconciled Depreciation | $6,592,000,000 | $7,013,000,000 | $6,290,000,000 | $5,064,000,000 |
| EBITDA (Bullshit earnings) | $16,783,000,000 | $18,127,000,000 | $9,557,000,000 | $41,031,000,000 |
| EBIT | $10,191,000,000 | $11,114,000,000 | $3,267,000,000 | $35,967,000,000 |
| Diluted Average Shares | $5,713,000,000 | $5,700,000,000 | $5,709,000,000 | $5,733,000,000 |
| Basic Average Shares | $5,683,000,000 | $5,664,000,000 | $5,643,000,000 | $5,608,000,000 |
| Diluted NI Availto Com Stockholders | $7,771,000,000 | $8,031,000,000 | $2,119,000,000 | $31,372,000,000 |
| Minority Interests | $-41,000,000 | $-31,000,000 | $-39,000,000 | $-35,000,000 |
| Tax Provision | $-266,000,000 | $-28,000,000 | $-1,115,000,000 | $3,328,000,000 |
| Other Special Charges | $1,057,000,000 | $567,000,000 | $474,000,000 | $230,000,000 |
| Impairment Of Capital Assets | $4,940,000,000 | $3,295,000,000 | $3,024,000,000 | $421,000,000 |
| Restructuring And Mergern Acquisition | $1,550,000,000 | $2,419,000,000 | $2,943,000,000 | $1,451,000,000 |
| Gain On Sale Of Security | $198,000,000 | $1,280,000,000 | $2,066,000,000 | $-959,000,000 |
| Amortization | $4,874,000,000 | $5,286,000,000 | $4,733,000,000 | $3,609,000,000 |
| Research And Development | $12,050,000,000 | $10,930,000,000 | $10,873,000,000 | $12,381,000,000 |
| Selling General And Administration | $13,794,000,000 | $14,730,000,000 | $14,771,000,000 | $13,677,000,000 |
| Gain On Sale Of Business | - | $525,000,000 | $222,000,000 | - |
| Write Off | - | $432,000,000 | $227,000,000 | $52,000,000 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-05-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-38,518,000,000 | $-35,736,000,000 | $-43,669,000,000 | $916,000,000 |
| Total Assets | $208,160,000,000 | $213,396,000,000 | $226,501,000,000 | $197,205,000,000 |
| Total Non Current Assets | $165,263,000,000 | $163,038,000,000 | $183,168,000,000 | $145,944,000,000 |
| Other Non Current Assets | $9,631,000,000 | $9,817,000,000 | $12,471,000,000 | $13,163,000,000 |
| Non Current Deferred Assets | $9,699,000,000 | $8,662,000,000 | $3,706,000,000 | $6,693,000,000 |
| Non Current Deferred Taxes Assets | $9,699,000,000 | $8,662,000,000 | $3,706,000,000 | $6,693,000,000 |
| Investmentin Financial Assets | $1,387,000,000 | $2,010,000,000 | $3,731,000,000 | $4,036,000,000 |
| Goodwill And Other Intangible Assets | $124,994,000,000 | $123,939,000,000 | $132,683,000,000 | $94,745,000,000 |
| Other Intangible Assets | $53,730,000,000 | $55,412,000,000 | $64,900,000,000 | $43,370,000,000 |
| Current Assets | $42,898,000,000 | $50,358,000,000 | $43,333,000,000 | $51,259,000,000 |
| Other Current Assets | $2,807,000,000 | $4,253,000,000 | $4,910,000,000 | $5,017,000,000 |
| Inventory | $10,654,000,000 | $10,851,000,000 | $10,189,000,000 | $8,981,000,000 |
| Receivables | $15,841,000,000 | $14,777,000,000 | $15,544,000,000 | $14,529,000,000 |
| Taxes Receivable | $3,967,000,000 | $3,314,000,000 | $3,978,000,000 | $3,577,000,000 |
| Accounts Receivable | $11,874,000,000 | $11,463,000,000 | $11,566,000,000 | $10,952,000,000 |
| Allowance For Doubtful Accounts Receivable | $-427,000,000 | $-438,000,000 | $-470,000,000 | $-449,000,000 |
| Gross Accounts Receivable | $12,301,000,000 | $11,901,000,000 | $12,036,000,000 | $11,401,000,000 |
| Cash Cash Equivalents And Short Term Investments | $13,596,000,000 | $20,477,000,000 | $12,690,000,000 | $22,732,000,000 |
| Cash And Cash Equivalents | $1,142,000,000 | $1,043,000,000 | $2,853,000,000 | $416,000,000 |
| Debt | ||||
| Net Debt | $62,819,000,000 | $62,606,000,000 | $67,992,000,000 | $34,443,000,000 |
| Total Debt | $63,961,000,000 | $63,649,000,000 | $70,845,000,000 | $34,859,000,000 |
| Long Term Debt And Capital Lease Obligation | $60,807,000,000 | $56,703,000,000 | $60,499,000,000 | $31,925,000,000 |
| Long Term Debt | $60,807,000,000 | $56,703,000,000 | $60,499,000,000 | $31,925,000,000 |
| Current Debt And Capital Lease Obligation | $3,154,000,000 | $6,946,000,000 | $10,346,000,000 | $2,934,000,000 |
| Current Debt | $3,154,000,000 | $6,946,000,000 | $10,346,000,000 | $2,934,000,000 |
| Other Current Borrowings | $3,154,000,000 | $4,493,000,000 | $2,381,000,000 | $2,934,000,000 |
| Liabilities | ||||
| Minimum Pension Liabilities | $75,000,000 | $191,000,000 | $128,000,000 | $248,000,000 |
| Total Liabilities Net Minority Interest | $121,385,000,000 | $124,899,000,000 | $137,213,000,000 | $101,289,000,000 |
| Total Non Current Liabilities Net Minority Interest | $84,401,000,000 | $81,904,000,000 | $89,419,000,000 | $59,151,000,000 |
| Other Non Current Liabilities | $14,727,000,000 | $14,151,000,000 | $16,540,000,000 | $13,182,000,000 |
| Derivative Product Liabilities | $834,000,000 | $701,000,000 | $1,039,000,000 | $959,000,000 |
| Tradeand Other Payables Non Current | $3,591,000,000 | $6,112,000,000 | $8,534,000,000 | $9,812,000,000 |
| Non Current Deferred Liabilities | $2,401,000,000 | $2,122,000,000 | $640,000,000 | $1,023,000,000 |
| Non Current Deferred Taxes Liabilities | $2,401,000,000 | $2,122,000,000 | $640,000,000 | $1,023,000,000 |
| Current Liabilities | $36,984,000,000 | $42,995,000,000 | $47,794,000,000 | $42,138,000,000 |
| Other Current Liabilities | $18,648,000,000 | $19,720,000,000 | $20,541,000,000 | $22,578,000,000 |
| Current Deferred Liabilities | $784,000,000 | $1,511,000,000 | $2,700,000,000 | $2,520,000,000 |
| Payables And Accrued Expenses | $10,788,000,000 | $10,980,000,000 | $11,431,000,000 | $10,699,000,000 |
| Payables | $10,788,000,000 | $10,980,000,000 | $11,431,000,000 | $10,699,000,000 |
| Dividends Payable | $2,445,000,000 | $2,437,000,000 | $2,372,000,000 | $2,303,000,000 |
| Total Tax Payable | $3,103,000,000 | $2,910,000,000 | $2,349,000,000 | $1,587,000,000 |
| Income Tax Payable | $3,103,000,000 | $2,910,000,000 | $2,349,000,000 | $1,587,000,000 |
| Accounts Payable | $5,240,000,000 | $5,633,000,000 | $6,710,000,000 | $6,809,000,000 |
| Equity | ||||
| Common Stock Equity | $86,476,000,000 | $88,203,000,000 | $89,014,000,000 | $95,661,000,000 |
| Total Equity Gross Minority Interest | $86,775,000,000 | $88,497,000,000 | $89,288,000,000 | $95,916,000,000 |
| Stockholders Equity | $86,476,000,000 | $88,203,000,000 | $89,014,000,000 | $95,661,000,000 |
| Other Equity Interest | $1,000,000 | - | - | - |
| Gains Losses Not Affecting Retained Earnings | $-8,070,000,000 | $-7,842,000,000 | $-7,961,000,000 | $-8,304,000,000 |
| Other Equity Adjustments | $-321,000,000 | $57,000,000 | $-217,000,000 | $-412,000,000 |
| Retained Earnings | $114,610,000,000 | $116,725,000,000 | $118,353,000,000 | $125,656,000,000 |
| Long Term Equity Investment | $235,000,000 | $217,000,000 | $11,637,000,000 | $11,033,000,000 |
| Other | ||||
| Treasury Shares Number | $3,935,000,000 | $3,926,000,000 | $3,916,000,000 | $3,903,000,000 |
| Ordinary Shares Number | $5,686,000,000 | $5,666,990,035 | $5,646,000,000 | $5,616,000,000 |
| Share Issued | $9,621,000,000 | $9,592,990,035 | $9,562,000,000 | $9,519,000,000 |
| Tangible Book Value | $-38,518,000,000 | $-35,736,000,000 | $-43,669,000,000 | $916,000,000 |
| Invested Capital | $150,437,000,000 | $151,852,000,000 | $159,859,000,000 | $130,520,000,000 |
| Working Capital | $5,914,000,000 | $7,363,000,000 | $-4,461,000,000 | $9,121,000,000 |
| Total Capitalization | $147,283,000,000 | $144,906,000,000 | $149,513,000,000 | $127,586,000,000 |
| Minority Interest | $299,000,000 | $294,000,000 | $274,000,000 | $256,000,000 |
| Foreign Currency Translation Adjustments | $-7,796,000,000 | $-7,984,000,000 | $-7,863,000,000 | $-8,360,000,000 |
| Unrealized Gain Loss | $-28,000,000 | $-106,000,000 | $-9,000,000 | $220,000,000 |
| Treasury Stock | $115,015,000,000 | $114,763,000,000 | $114,487,000,000 | $113,969,000,000 |
| Additional Paid In Capital | $94,469,000,000 | $93,603,000,000 | $92,631,000,000 | $91,802,000,000 |
| Capital Stock | $481,000,000 | $480,000,000 | $478,000,000 | $476,000,000 |
| Common Stock | $481,000,000 | $480,000,000 | $478,000,000 | $476,000,000 |
| Employee Benefits | $2,041,000,000 | $2,115,000,000 | $2,167,000,000 | $2,250,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,041,000,000 | $2,115,000,000 | $2,167,000,000 | $2,250,000,000 |
| Current Deferred Revenue | $784,000,000 | $1,511,000,000 | $2,700,000,000 | $2,520,000,000 |
| Commercial Paper | $0 | $2,453,000,000 | $7,965,000,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,610,000,000 | $3,838,000,000 | $2,776,000,000 | $3,407,000,000 |
| Investments And Advances | $1,622,000,000 | $2,227,000,000 | $15,368,000,000 | $15,069,000,000 |
| Held To Maturity Securities | $48,000,000 | $45,000,000 | $47,000,000 | $48,000,000 |
| Available For Sale Securities | $1,339,000,000 | $1,965,000,000 | $3,684,000,000 | $3,988,000,000 |
| Goodwill | $71,264,000,000 | $68,527,000,000 | $67,783,000,000 | $51,375,000,000 |
| Net PPE | $19,317,000,000 | $18,393,000,000 | $18,940,000,000 | $16,274,000,000 |
| Accumulated Depreciation | $-17,386,000,000 | $-16,483,000,000 | $-16,045,000,000 | $-15,174,000,000 |
| Gross PPE | $36,703,000,000 | $34,876,000,000 | $34,985,000,000 | $31,448,000,000 |
| Construction In Progress | $4,805,000,000 | $4,937,000,000 | $5,925,000,000 | $4,875,000,000 |
| Machinery Furniture Equipment | $21,854,000,000 | $20,611,000,000 | $19,662,000,000 | $17,372,000,000 |
| Buildings And Improvements | $9,744,000,000 | $9,036,000,000 | $9,046,000,000 | $8,832,000,000 |
| Land And Improvements | $299,000,000 | $291,000,000 | $353,000,000 | $368,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $4,113,000,000 | $3,775,000,000 | $3,495,000,000 | $2,603,000,000 |
| Work In Process | $5,634,000,000 | $6,101,000,000 | $5,688,000,000 | $5,519,000,000 |
| Raw Materials | $907,000,000 | $976,000,000 | $1,007,000,000 | $859,000,000 |
| Other Short Term Investments | $12,454,000,000 | $19,434,000,000 | $9,837,000,000 | $22,316,000,000 |
| Other Properties | - | $1,000,000 | $-1,000,000 | $1,000,000 |
| Other Inventories | - | $-1,000,000 | $-1,000,000 | - |
| Preferred Stock | - | - | $0 | $0 |
| Other Investments | - | - | - | - |
Fetched: 2026-05-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $9,075,000,000 | $9,835,000,000 | $4,793,000,000 | $26,031,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $11,704,000,000 | $12,744,000,000 | $8,700,000,000 | $29,267,000,000 |
| Cash Flow From Continuing Operating Activities | $11,705,000,000 | $12,743,000,000 | $8,702,000,000 | $29,267,000,000 |
| Cash From Discontinued Operating Activities | - | - | $0 | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-2,629,000,000 | $-2,909,000,000 | $-3,907,000,000 | $-3,236,000,000 |
| Investing Cash Flow | $-1,351,000,000 | $2,652,000,000 | $-32,278,000,000 | $-15,783,000,000 |
| Cash Flow From Continuing Investing Activities | $-1,351,000,000 | $2,654,000,000 | $-32,277,000,000 | $-15,783,000,000 |
| Net Other Investing Changes | $165,000,000 | - | $-180,000,000 | $-192,000,000 |
| Cash From Discontinued Investing Activities | - | - | $0 | $0 |
| Financing Activities | ||||
| Financing Cash Flow | $-10,304,000,000 | $-17,140,000,000 | $26,066,000,000 | $-14,834,000,000 |
| Cash Flow From Continuing Financing Activities | $-10,303,000,000 | $-17,140,000,000 | $26,067,000,000 | $-14,834,000,000 |
| Net Other Financing Charges | $-459,000,000 | $-469,000,000 | $-632,000,000 | $-335,000,000 |
| Cash Dividends Paid | $-9,771,000,000 | $-9,512,000,000 | $-9,247,000,000 | $-8,983,000,000 |
| Common Stock Dividend Paid | $-9,771,000,000 | $-9,512,000,000 | $-9,247,000,000 | $-8,983,000,000 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-2,000,000,000 |
| Net Common Stock Issuance | - | $0 | $0 | $-2,000,000,000 |
| Dividends Received Cfi | - | $0 | $0 | $3,960,000,000 |
| Cash From Discontinued Financing Activities | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-9,752,000,000 | $-16,066,000,000 | $-2,572,000,000 | $-7,407,000,000 |
| Issuance Of Debt | $9,678,000,000 | $8,907,000,000 | $38,517,000,000 | $3,891,000,000 |
| Interest Paid Supplemental Data | $2,739,000,000 | $3,227,000,000 | $2,215,000,000 | $1,442,000,000 |
| Income Tax Paid Supplemental Data | $4,688,000,000 | $3,605,000,000 | $3,147,000,000 | $7,867,000,000 |
| End Cash Position | $1,197,000,000 | $1,107,000,000 | $2,917,000,000 | $468,000,000 |
| Beginning Cash Position | $1,107,000,000 | $2,917,000,000 | $468,000,000 | $1,983,000,000 |
| Effect Of Exchange Rate Changes | $41,000,000 | $-66,000,000 | $-40,000,000 | $-165,000,000 |
| Changes In Cash | $49,000,000 | $-1,744,000,000 | $2,489,000,000 | $-1,350,000,000 |
| Net Issuance Payments Of Debt | $-74,000,000 | $-7,159,000,000 | $35,945,000,000 | $-3,516,000,000 |
| Net Short Term Debt Issuance | $-2,995,000,000 | $-4,909,000,000 | $7,683,000,000 | $-218,000,000 |
| Short Term Debt Payments | $-2,995,000,000 | $-13,816,000,000 | $-3,000,000 | $-4,109,000,000 |
| Short Term Debt Issuance | $0 | $8,907,000,000 | $7,686,000,000 | $3,891,000,000 |
| Net Long Term Debt Issuance | $2,921,000,000 | $-2,250,000,000 | $28,262,000,000 | $-3,298,000,000 |
| Long Term Debt Payments | $-6,757,000,000 | $-2,250,000,000 | $-2,569,000,000 | $-3,298,000,000 |
| Long Term Debt Issuance | $9,678,000,000 | $0 | $30,831,000,000 | $0 |
| Net Investment Purchase And Sale | $1,729,000,000 | $-1,479,000,000 | $15,239,000,000 | $6,682,000,000 |
| Sale Of Investment | $19,054,000,000 | $8,834,000,000 | $46,417,000,000 | $45,462,000,000 |
| Purchase Of Investment | $-17,325,000,000 | $-10,313,000,000 | $-31,178,000,000 | $-38,780,000,000 |
| Net Business Purchase And Sale | $-616,000,000 | $7,040,000,000 | $-43,430,000,000 | $-22,997,000,000 |
| Sale Of Business | $6,311,000,000 | $7,040,000,000 | $0 | $0 |
| Purchase Of Business | $-6,927,000,000 | $0 | $-43,430,000,000 | $-22,997,000,000 |
| Net PPE Purchase And Sale | $-2,629,000,000 | $-2,909,000,000 | $-3,907,000,000 | $-3,236,000,000 |
| Purchase Of PPE | $-2,629,000,000 | $-2,909,000,000 | $-3,907,000,000 | $-3,236,000,000 |
| Change In Working Capital | $-5,354,000,000 | $-3,066,000,000 | $-2,172,000,000 | $-5,639,000,000 |
| Change In Other Working Capital | $-2,805,000,000 | $-1,345,000,000 | $-982,000,000 | $-545,000,000 |
| Change In Other Current Liabilities | $-3,667,000,000 | $-3,115,000,000 | $595,000,000 | $-1,449,000,000 |
| Change In Other Current Assets | $1,289,000,000 | $3,380,000,000 | $-663,000,000 | $-4,506,000,000 |
| Change In Payables And Accrued Expense | $-469,000,000 | $-1,023,000,000 | $-300,000,000 | $1,191,000,000 |
| Change In Payable | $-469,000,000 | $-1,023,000,000 | $-300,000,000 | $1,191,000,000 |
| Change In Account Payable | $-469,000,000 | $-1,023,000,000 | $-300,000,000 | $1,191,000,000 |
| Change In Inventory | $561,000,000 | $-854,000,000 | $-1,169,000,000 | $-591,000,000 |
| Change In Receivables | $-263,000,000 | $-109,000,000 | $347,000,000 | $261,000,000 |
| Changes In Account Receivables | $-263,000,000 | $-109,000,000 | $347,000,000 | $261,000,000 |
| Other Non Cash Items | $-1,257,000,000 | $-2,271,000,000 | $-4,281,000,000 | $-400,000,000 |
| Stock Based Compensation | $799,000,000 | $877,000,000 | $525,000,000 | $872,000,000 |
| Asset Impairment Charge | $5,270,000,000 | $4,242,000,000 | $9,607,000,000 | $1,733,000,000 |
| Deferred Tax | $-2,133,000,000 | $-2,102,000,000 | $-3,442,000,000 | $-3,764,000,000 |
| Deferred Income Tax | $-2,133,000,000 | $-2,102,000,000 | $-3,442,000,000 | $-3,764,000,000 |
| Depreciation Amortization Depletion | $6,592,000,000 | $7,013,000,000 | $6,290,000,000 | $5,064,000,000 |
| Depreciation And Amortization | $6,592,000,000 | $7,013,000,000 | $6,290,000,000 | $5,064,000,000 |
| Net Income From Continuing Operations | $7,787,000,000 | $8,051,000,000 | $2,173,000,000 | $31,401,000,000 |
| Common Stock Payments | - | $0 | $0 | $-2,000,000,000 |
| Earnings Losses From Equity Investments | - | - | - | - |
Fetched: 2026-05-19